The canonical Wnt/β-catenin pathway: From the history of its discovery to clinical application


Cite item

Full Text

Abstract

The Wnt/β signaling pathway (Wnt-SP) is a phylogenetically ancient mechanism that regulates development and maintains tissue homeostasis through the control of cell proliferation, differentiation, migration, and apoptosis. The accurate regulation of the canonical Wnt/β-catenin signaling pathway (Wnt-SP) is critical for embryogenesis and postnatal development; and impaired signal transduction at one of its stages leads to various diseases, including organ malformations, cancers, metabolic and neurodegenerative disorders. The literature review discusses the biological role of the canonical Wnt-SP in the development of the skeleton and in the remodeling of bone tissue. The Wnt signal transmission changes observed during genetic mutations cause various human skeletal diseases. Understanding the functional mechanism involved in the development of bone abnormality could open new horizons in the treatment of osteoporosis, by affecting the Wnt-SP. The design of antibodies to sclerostin, a Wnt-SP inhibitor, is most promising now. The paper summarizes the studies that have investigated the canonical Wnt-SP and designed drugs to treat osteoporosis.

References

  1. Kaunitz AM, McClung MR, Feldman RG, Wysocki S. Postmenopausal osteoporosis: Fracture risk and prevention. JFamPract. 2009;58(11):1-6.
  2. Дедов И.И., Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. Остеопороз — от редкого симптома эндокринных болезней до безмолвной эпидемии XX—XXI века. Проблемыэндокринологии. 2011:57(1):34-45. doi: 10.14341/probl201157135-45
  3. Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032-1045. doi: 10.4065/83.9.1032
  4. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1—34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30(3):312-321.
  5. Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980;287(5785):795-801.
  6. Nusse R, Varmus H. Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J. 2012;31(12):2670-2684. doi: 10.1038/emboj.2012.146
  7. De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, Myers A, Sáez K, Henríquez JP, Zhao A, Wollmer MA, Nitsch RM, Hock C, Morris CM, Hardy J, Moon RT. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer’s disease. Proc Natl Acad Sci USA. 2007;104(22):9434-9439.
  8. Polakis P. The many ways of wnt in cancer. Curr Opin Genet Dev. 2007;17(1):45-51.
  9. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene. 2004;341:19-39.
  10. Niemann S, Zhao C, Pascu F, Stahl U, Aulepp U, Niswander L, Weber JL, Müller U. Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. Am J Hum Genet. 2004;74(3):558-563.
  11. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513-1521.
  12. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML; Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513-523.
  13. Toomes C, Bottomley HM, Jackson RM, Towns KV, Scott S, Mackey DA, Craig JE, Jiang L, Yang Z, Trembath R, Woodruff G, Gregory-Evans CY, Gregory-Evans K, Parker MJ, Black GC, Downey LM, Zhang K, Inglehearn CF. Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet. 2004;74:721-730.
  14. Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleff I, Pirinen S, Nieminen P. Mutations in AXIN2 cause familial tooth agenesis and redispose to colorectal cancer. Am J Hum Genet. 2004;74:1043-1050.
  15. Morin PJ. beta-catenin signaling and cancer. Bioessays. 1999;21(12):1021-1030.
  16. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000;24:245-250.
  17. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469-480.
  18. Hoeppner LH, Secreto FJ, Westendorf JJ. Wntsignaling as a therapeutictarget for bone diseases. Expert Opin Ther Targets.2009;13(4):485-496. doi: 10.1517/14728220902841961
  19. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem. 2005;280(50):41342-41351.
  20. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA.2005;102(9):3324-3329.
  21. Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116(5):1202-1209.
  22. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ. Update on Wnt signaling in bone cell biology and bone disease. Gene. 2012;492(1):1-18. doi: 10.1016/j.gene.2011.10.044
  23. van Amerongen R, Mikels A, Nusse R. Alternative wnt signaling is initiated by distinct receptors. Sci Signal. 2008;1(35):re9. doi: 10.1126/scisignal.135re9
  24. Mikels AJ, Nusse R. Purified wnt5a protein activates or inhibits beta-catenin-tcf signaling depending on receptor context. PLoS Biol. 2006;4(4):e115.
  25. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast an chondrocyte differentiation uring vertebrate skeletogenesis. Dev Cell. 2005;8(5):739-750.
  26. Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006;133(16):3231-3244.
  27. Kahn M. Can we safely target the WNT pathway? NatRevDrugDiscov. 2014;13(7):513-532. doi: 10.1038/nrd4233
  28. Гребенникова Т.А., Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А., Дедов И.И. Эпигенетические аспекты остеопороза. Вестник РАМН. 2015;70(5):541-548. doi: 10.15690/vramn.v70.i5.1440
  29. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, Shaughnessy JD Jr. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009;113(3):517-25. doi: 10.1182/blood-2008-03-145169
  30. Bodine PV, Stauffer B, Ponce-de-Leon H, Bhat RA, Mangine A, Seestaller-Wehr LM, Moran RA, Billiard J, Fukayama S, Komm BS, Pitts K, Krishnamurthy G, Gopalsamy A, Shi M, Kern JC, Commons TJ, Woodworth RP, Wilson MA, Welmaker GS, Trybulski EJ, Moore WJ. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone. 2009;44(6):1063-1068. doi: 10.1016/j.bone.2009.02.013
  31. Witte F, Dokas J, Neuendorf F, Mundlos S, Stricker S. Comprehensive expression analysis of all Wnt genes and their major secreted antagonists during mouse limb development and cartilage differentiation. Gene Expr Patterns.2009;9(4):215-223. doi: 10.1016/j.gep.2008.12.009
  32. Malinauskas T, Aricescu AR, Lu W, Siebold C, Jones EY. Modular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1. Nat Struct Mol Biol.2011;18(8):886-893. doi: 10.1038/nsmb.2081.
  33. Krause C, Korchynskyi O,de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN, Mueller TD,Löwik CW, ten Dijke P. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem.2010;285(53):41614-41626. doi: 10.1074/jbc.M110.153890
  34. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L,de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med.2004;199(6):805-814.
  35. Lintern KB, Guidato S, Rowe A, Saldanha JW, Itasaki N. Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J Biol Chem. 2009;284(34):23159-23168. doi: 10.1074/jbc.M109.025478
  36. Belaya ZE, Rozhinskaya LY, Melnichenko GA, Dragunova NV, Iljin AV, Dzeranova LK, Dedov II, Solodovnikov AG. Serum extracellular secreted antagonists of the canonical WNT/ β-catenin signaling pathway in patients with Cushing’s syndrome. Osteoporosis International. 2013;24(8):2191-2199.
  37. Saarinen A, Välimäki VV, Välimäki MJ, Löyttyniemi E, Auro K, Uusen P, Kuris M, Lehesjoki AE, Mäkitie O. The A1330V polymorphism of the low-density lipoprotein receptor-related protein 5 gene (LRP5) associates with low peak bone mass in young healthy men. Bone. 2007;40(4):1006-1012.
  38. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W 2003 Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet. 2003;72(3):763-771.
  39. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science. 2007;315(5816):1278-1282.
  40. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet.2001;10(5):537-543.
  41. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet.2001;68(3):577-589.
  42. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA 2nd, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a wnt coreceptor. J Cell Biol. 2002;157(2):303-314.
  43. Williams BO, Insogna KL. Perspective Where Wnts Went: The Exploding Field of Lrp5 and Lrp6 Signaling in Bone. J Bone Miner Res. 2009;24(2):171-178. doi: 10.1359/jbmr.081235
  44. Carter M, Chen X, Slowinska B, Minnerath S, Glickstein S, Shi L, Campagne F, Weinstein H, Ross ME. Crooked tail (Cd) model of human folate-responsive neural tube defects is mutated in Wnt coreceptor lipoprotein receptorrelated protein 6. Proc Natl Acad Sci USA. 2005;102(36):12843-12848.
  45. Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML, Williams BO. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res. 2004;19(12):2033-2040.
  46. Kokubu C, Heinzmann U, Kokubu T, Sakai N, Kubota T, KawaiM, WahlMB,Galceran J, Grosschedl R, OzonoK, Imai K. Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development. 2004;131(21):5469-5480.
  47. Kubota T, Michigami T, Sakaguchi N, Kokubu C, Suzuki A, Namba N, Sakai N, Nakajima S, Imai K, Ozono K. Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd. J Bone Miner Res. 2008;23(10):1661-1671. doi: 10.1359/jbmr.080512
  48. Larsson S. Anti-sclerostin — is there an indication? Injury. 2016;47(1):31-35. doi: 10.1016/S0020-1383(16)30008-0
  49. Semënov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280(29):26770-26775.
  50. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280(20):19883-19887.
  51. Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Löwik CW, Hamersma H, Beighton P, Papapoulos SE. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab. 2005;90(12):6392-6395.
  52. Wengenroth M, Vasvari G, Federspil PA, Mair J, Schneider P, Stippich C. Case 150: Van Buchem disease (hyperostosis corticalis generalisata). Radiology. 2009;253(1):272-276. doi: 10.1148/radiol.2531080011
  53. Uitterlinden AG, Arp PP, Paeper BW, Charmley P, Proll S, Rivadeneira F, Fang Y, van Meurs JB, Britschgi TB, Latham JA, Schatzman RC, Pols HA, Brunkow ME. Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum Genet.2004;75(6):1032-1045.
  54. Regard JB, Zhong Z, Williams BO, Yang Y. Wnt signaling in bone development and disease: making stronger bone with Wnts. Cold Spring Harb Perspect Biol. 2012;4(12).pii:a007997. doi: 10.1101/cshperspect.a007997
  55. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR 3rd, Nusse R. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 2003;423(6938):448-452.
  56. Wagner ER, Zhu G, Zhang BQ, Luo Q, Shi Q, Huang E, Gao Y, Gao JL, Kim SH, Rastegar F, Yang K, He BC, Chen L, Zuo GW, Bi Y, Su Y, Luo J, Luo X, Huang J, Deng ZL, Reid RR, Luu HH, Haydon RC, He TC. The therapeutic potential of the Wnt signaling pathway in bone disorders. Curr Mol Pharmacol.2011;4(1):14-25. doi: 10.2174/1874467211104010014
  57. Pai R, Tarnawski AS, Tran T. Deoxycholic acid activates betacatenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell. 2004;15(5):2156-2163.
  58. Kubota T, Michigami T, Ozono K. Wnt signaling in bone metabolism. JBone Miner Metab. 2009;27(3):265-271. doi: 10.1007/s00774-009-0064-8
  59. Piters E, Boudin E, Van Hul W. Wnt signaling: a win for bone. Arch Biochem Biophys. 2008;473(2):112-116. doi: 10.1016/j.abb.2008.03.006
  60. Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol. 2009;5(1):20-27. doi: 10.1038/ncprheum0977
  61. Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ, Sato M, Bryant HU, Ma YL. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res. 2006;21(6):910-920.
  62. Vestergaard P, Rejnmark L, Mosekilde L. Reduced relative risk of fractures among users of lithium. Calcif Tissue Int. 2005;77(1):1-8.
  63. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004;10(1):55-63.
  64. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, Zhou L, Feng T, King D, Cheng H, Breyer B, Peabody T, Simon MA, Montag AG, He TC. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer. 2002;102(4):338-342.
  65. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87(2):159-170.
  66. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657-667.
  67. Luo X, Chen J, Song WX, Tang N, Luo J, Deng ZL, Sharff KA, He G, Bi Y, He BC, Bennett E, Huang J, Kang Q, Jiang W, Su Y, Zhu GH, Yin H, He Y, Wang Y, Souris JS, Chen L, Zuo GW, Montag AG, Reid RR, Haydon RC, Luu HH, He TC. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest. 2008;88(12):1264-1277. doi: 10.1038/labinvest.2008.98
  68. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma Development and stem cell differentiation. Clin Orthop Relat. Rres. 2008;466(9):2114-21130. doi: 10.1007/s11999-008-0335-z
  69. Kneissel M. The promise of sclerostin inhibition for the treatment of osteoporosis. IBMS BoneKEy. 2009;6:259-264.
  70. Sims NA, Chia LY. Regulation of sclerostin expression by paracrine and endocrine factors. Clin Rev Bone Miner Metab. 2012;10:98-107.
  71. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146(11):4577-4583.
  72. Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Gillespie MT, Walsh NC, Chia LY, Quinn JM, Martin TJ, Sims NA. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone. 2010;46(6):1486-1497. doi: 10.1016/j.bone.2010.02.018
  73. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008;283(9):5866-5875.
  74. Silverman SL. Sclerostin. J Osteoporos.2010;2010:941419. doi: 10.4061/2010/941419
  75. Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011;26(1):27-34. doi: 10.1002/jbmr.128
  76. van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011;26(12):2804-2811. doi: 10.1002/jbmr.474
  77. Ke HZ, Xiang JJ, Li X. Inhibition of sclerostin by systemic treatment with a sclerostin monoclonal antibody enhances fracture healing in mice and rats. Proceedings of the 55th Annual Orthopedic Research Society Meeting, Las Vegas, Nev, USA, 2009.
  78. Li X, Warmington K, Niu Q et al. Increased bone formation and bone mass by sclerostin antibody was not blunted by pretreatment with alendronate in ovariectomized rats with established osteopenia. Proceedings of the ASBMR Annual Meeting, 2009.
  79. Halleux C, Hu S, Diefenbach B et al. Infrequent cotreatment and sequential treatment of antisclerostin antibody with zoledronic acid restores and maintains bone mass in murine osteoporosis models. Proceedings of the ASBMR Annual Meeting, 2009.
  80. Lane N, Dai W, Yao W et al. Treatment with sclerostin inhibitors increases bone formation in male mice. Proceedings of the ASBMR Annual Meeting, 2009
  81. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res.2010;25(5):948-959. doi: 10.1002/jbmr.14
  82. Yavropoulou M, Xygonakis C, Lolou M, Karadimou F, Yovos J. The sclerostin story: From human genetics to the development of novel anabolic treatment for osteoporosis. Hormones (Athens).2014;13(4):323-337. doi: 10.14310/horm.2002.1552
  83. Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, Jang G. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2014;54(2):168-178. doi: 10.1002/jcph.239
  84. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412-420. doi: 10.1056/NEJMoa1305224
  85. McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res. 2014;29(4):935-943. doi: 10.1002/jbmr.2092
  86. Recker R, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, Chiang AY, Hu L, Krege JH, Sowa H, Mitlak BH, Myers SL. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30(2):216-224. doi: 10.1002/jbmr.2351
  87. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6(10):e25900. doi: 10.1371/journal.pone.0025900
  88. Becker CB. Sclerostin inhibition for osteoporosis--a new approach. N Engl J Med.2014;370(5):476-477. doi: 10.1056/NEJMe1315500

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies